Adalimumab — clinical trials using this drug

Public-registry trials using Adalimumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Adalimumab appears in 1 registered trial Eichor's radar has found, sponsored by Jeffrey J Crowley MD, the most recent registered as Phase 2 / Phase 3, with a planned enrollment of 56. Registered timeline: 2017–2018. The registry holds 2,534 registered studies for Psoriasis.

Trial	Sponsor	Condition	Phase	Sites
MAP Study: Methotrexate and Adalimumab in Psoriasis	Jeffrey J Crowley MD	Psoriasis	PHASE2 / PHASE3	4

About this study

MAP Study: Methotrexate and Adalimumab in Psoriasis

Status	Completed · planned start 2017-04
Primary completion	2018-12
Enrollment target	56 participants
Design	Randomized · Parallel · Phase 2 / Phase 3 · 2 arms
Who it enrolls	All sexes · 18 Years and older — full criteria are on the study record
Locations	4 listed in United States

All fields verbatim from the ClinicalTrials.gov record for NCT03217734.

Origin & regulatory history

First FDA approval	HUMIRA — December 2002 (application BLA125057, currently held by ABBVIE INC)
Approval timeline	HUMIRA 2002 (ABBVIE INC) → AMJEVITA 2016 (AMGEN INC) → CYLTEZO 2017 (BOEHRINGER INGELHEIM) → HYRIMOZ 2018 (SANDOZ INC) → HADLIMA 2019 (SAMSUNG BIOEPIS CO LTD) → ABRILADA 2019 (PFIZER INC) → HULIO 2020 (MYLAN PHARMS INC) → YUSIMRY 2021 (COHERUS BIOSCIENCES INC) → +3 more brands
Also known as	HUMIRA · AMJEVITA · CYLTEZO · HYRIMOZ · HADLIMA · ABRILADA · HULIO · YUSIMRY · IDACIO · YUFLYMA
Approved applications	11 — a multi-source (generic) drug
Forms & routes	Injectable, Syringe, Vial · Injection, Subcutaneous
Registry-wide use	795 registered studies all-time · 58 currently recruiting

Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.

Psoriasis drug landscape

The public registry holds 2,534 registered studies for Psoriasis. Compounds appearing across the 200 most recently updated registry entries:

Placebo ×49 Guselkumab ×17 bimekizumab ×12 Deucravacitinib ×12 JNJ-77242113 ×8 Zasocitinib ×8 Methotrexate ×7 ustekinumab ×7 Apremilast ×6 Risankizumab ×6 Tirzepatide ×6 Ixekizumab ×5 Tofacitinib ×4 Envudeucitinib ×3 Etanercept ×3 HPP737 ×3 Secukinumab ×3 Sonelokimab ×3 Spesolimab ×3 Azathioprine ×2 Certolizumab ×2 Cyclosporine ×2 Deucravacitinib Matching Placebo ×2 Diet ×2 Golimumab ×2 HPP737 and placebo ×2 Hydroxychloroquine ×2 Icotrokinra ×2 Infliximab ×2

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related drugs & trials

Trialed alongside

Other Psoriasis drugs

← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →